Trials / Completed
CompletedNCT04409509
Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)
A Phase 2, Multicenter, Double Blind, Randomized, Placebo-Controlled Study to Evaluate CSL312 in Coronavirus Disease 2019 (COVID 19)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 124 (actual)
- Sponsor
- CSL Behring · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, phase 2, multicenter, randomized, double blind, placebo controlled, parallel group study to assess the safety and efficacy of CSL312 administered intravenously, in combination with standard of care (SOC) treatment, in patients with Coronavirus disease 2019 (COVID 19)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Garadacimab, Factor XIIa Antagonist Monoclonal Antibody | Garadacimab, Factor XIIa Antagonist Monoclonal Antibody administered intravenously |
| DRUG | Placebo | CSL312 diluent administered intravenously |
Timeline
- Start date
- 2020-07-01
- Primary completion
- 2021-01-12
- Completion
- 2021-01-12
- First posted
- 2020-06-01
- Last updated
- 2022-01-24
- Results posted
- 2022-01-24
Locations
14 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04409509. Inclusion in this directory is not an endorsement.